185 related articles for article (PubMed ID: 20368536)
1. Small tumor size and node-negative HER2-positive breast cancer: a step forward for a better treatment?
Crivellari D; Molino A
J Clin Oncol; 2010 Jun; 28(16):e257; author reply e258-9. PubMed ID: 20368536
[No Abstract] [Full Text] [Related]
2. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
[TBL] [Abstract][Full Text] [Related]
3. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
[TBL] [Abstract][Full Text] [Related]
6. The natural history of breast carcinoma in the elderly: implications for screening and treatment.
Singh R; Hellman S; Heimann R
Cancer; 2004 May; 100(9):1807-13. PubMed ID: 15112260
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
8. Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?
Pignol JP; Rakovitch E; Olivotto IA
J Clin Oncol; 2011 Jul; 29(21):2841-3. PubMed ID: 21670459
[No Abstract] [Full Text] [Related]
9. Negative margin status improves local control in conservatively managed breast cancer patients.
Obedian E; Haffty BG
Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
[TBL] [Abstract][Full Text] [Related]
10. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
[TBL] [Abstract][Full Text] [Related]
11. [Breast cancer treatment].
Duodecim; 2005; 121(3):317-8. PubMed ID: 15787290
[No Abstract] [Full Text] [Related]
12. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer.
Carlson RW; Wheatley K
Cancer Treat Rev; 2004 Feb; 30(1):131-7. PubMed ID: 14766131
[No Abstract] [Full Text] [Related]
14. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
15. Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer.
Tan YY; Wu CT; Fan YG; Hwang S; Ewing C; Lane K; Esserman L; Lu Y; Treseler P; Morita E; Leong SP
Breast J; 2005; 11(5):338-43. PubMed ID: 16174155
[TBL] [Abstract][Full Text] [Related]
16. Disease related indicators for a proper choice of adjuvant treatments.
Hayes DF
Breast; 2011 Oct; 20 Suppl 3():S162-4. PubMed ID: 22015287
[TBL] [Abstract][Full Text] [Related]
17. The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.
Zork NM; Komenaka IK; Pennington RE; Bowling MW; Norton LE; Clare SE; Goulet RJ
Ann Surg; 2008 Aug; 248(2):280-5. PubMed ID: 18650639
[TBL] [Abstract][Full Text] [Related]
18. 5-year follow-up after sentinel node mapping for breast cancer demonstrates better than expected treatment outcomes.
Fuhrman GM; Gambino J; Bolton JS; Farr G; Jiang X
Am Surg; 2005 Jul; 71(7):564-9; discussion 569-70. PubMed ID: 16089119
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy in stage III breast cancer.
Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
[TBL] [Abstract][Full Text] [Related]
20. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
